Key Takeaways
- •The pharmaceutical manufacturing landscape continues to shift as MacroGenics, a biotechnology company focused on antibody-based immunotherapies, finalized an agreement to sell its clinical and commercial drug substance production portfolio to Bora Pharmaceuticals.
- •MacroGenics built its manufacturing capabilities to support its own pipeline of monoclonal antibodies and bispecific molecules, including its approved HER2-targeting agent margetuximab (Margenza).
- •Bora, a Taiwan-headquartered CDMO with a growing global footprint, acquires a fully validated facility equipped with mammalian cell culture bioreactors, purification trains, and quality control labs.
Bora Acquires MacroGenics Manufacturing for $122.5M
The pharmaceutical manufacturing landscape continues to shift as MacroGenics, a biotechnology company focused on antibody-based immunotherapies, finalized an agreement to sell its clinical and commercial drug substance production portfolio to Bora Pharmaceuticals. The deal includes an upfront cash payment of $122.5 million, granting Bora full ownership of the manufacturing facilities and related assets.
MacroGenics built its manufacturing capabilities to support its own pipeline of monoclonal antibodies and bispecific molecules, including its approved HER2-targeting agent margetuximab (Margenza). The company’s manufacturing arm handled both early-stage clinical supply and later-stage commercial production. By divesting these operations, MacroGenics can redirect capital and management attention toward research and development, a move that mirrors strategies seen across the biotech sector where smaller firms sell facilities to larger contract development and manufacturing organizations (CDMOs) to avoid the high fixed costs of internal production.
Bora, a Taiwan-headquartered CDMO with a growing global footprint, acquires a fully validated facility equipped with mammalian cell culture bioreactors, purification trains, and quality control labs. The site has a history of producing biologic drug substances under current Good Manufacturing Practices (cGMP). For Bora, this purchase rapidly expands its capacity to serve clients needing commercial-scale monoclonal antibody manufacturing, a market segment that has experienced capacity constraints in recent years due to the boom in biologic drug approvals.
Industry analysts note that such transactions help balance the supply-demand equation for biologics manufacturing. According to a 2023 report by the International Society for Pharmaceutical Engineering, global monoclonal antibody production capacity utilization hovered around 75 percent, leaving room for further specialization. Bora’s acquisition of MacroGenics’ manufacturing site gives the CDMO access to a trained workforce, existing regulatory filings, and a pipeline of potential future clients seeking a proven facility.
The deal is expected to close in the second quarter of 2025, pending customary regulatory approvals. MacroGenics stated it will initially lease back a portion of the facility for continued production of its own pipeline while Bora seeks to fill remaining capacity with external contracts.
West Pharma Reports Cybersecurity Issue
West Pharmaceutical Services, a global leader in drug packaging and delivery systems, disclosed a cybersecurity incident that has drawn attention to the vulnerability of pharmaceutical supply chain IT systems. The company made the announcement through its official channels, though details about the nature of the attack, its origin, and the extent of data or operational impact remain limited.
Cybersecurity experts have long warned that the pharmaceutical sector is an attractive target for malicious actors because of the sensitive intellectual property and personal health data it handles. In the case of West Pharma, the company provides rubber stoppers, syringe components, and packaging systems that are critical to drug sterility and stability. A breach could disrupt production lines or alter quality documentation.
The company stated that it has activated standard incident response protocols, which typically include isolating affected systems, engaging forensic investigators, notifying law enforcement, and communicating with customers. West Pharma’s disclosure reflects a growing trend toward proactive transparency. Under regulations such as the U.S. Securities and Exchange Commission’s cybersecurity rules, publicly traded companies are required to disclose material cybersecurity incidents within four business days.
For drug manufacturers that rely on West Pharma’s components, the key concern is whether the attack could delay shipments or compromise product integrity. To date, no reports of product contamination or supply interruption have emerged. However, the event serves as a reminder that pharmaceutical quality depends not just on drug makers themselves but on the security of every partner in the supply chain.
Updates on Bavarian Nordic and OrganaBio
Two other industry developments round out recent manufacturing news.
Bavarian Nordic, the Danish vaccine company known for its smallpox and mpox vaccines (including the Jynneos vaccine used during the 2022 mpox outbreak), was mentioned alongside other recent announcements. The company has been expanding its production capacity to meet global demand for its live-attenuated, non-replicating viral vector platform. While no specific new deal or regulatory event was detailed in the current report, Bavarian Nordic’s presence in industry news typically signals ongoing contract manufacturing partnerships or supply agreements for pandemic preparedness. The company manufactures its vaccines at its own facilities in Denmark and Switzerland, but it also collaborates with fill-finish partners for global distribution.
OrganaBio, a biosourcing and CDMO company specializing in cell and gene therapy materials, announced the launch of a new CDMO subsidiary. This subsidiary expands OrganaBio’s service offerings in contract development and manufacturing. The company originally focused on providing primary human cells and tissue-derived starting materials for research and preclinical use. With the new subsidiary, it can now offer end-to-end production support for clients developing cell therapies, including lentiviral vector manufacturing, cell processing, and quality testing.
The cell and gene therapy CDMO market has grown rapidly. According to a 2024 analysis by the Alliance for Regenerative Medicine, there were over 1,200 active clinical trials using these modalities. Yet manufacturing complexity remains a major bottleneck. Many small biotechs lack the in-house expertise to produce high-quality viral vectors or to optimize cell expansion protocols. OrganaBio’s move aims to bridge that gap by leveraging its existing supply channels for cells and turning them into a full-service manufacturing platform.
Frequently Asked Questions
Q: What does the Bora acquisition of MacroGenics manufacturing mean for MacroGenics’ existing drugs?
A: MacroGenics will lease back a portion of the facility to continue producing its own pipeline drugs, such as margetuximab, during a transition period. Bora will take over full operational control and seek to sell excess capacity to other biotech companies. The deal does not involve MacroGenics’ intellectual property or marketing rights; it only transfers the physical manufacturing assets.
Q: Could the West Pharma cybersecurity attack affect the supply of drug packaging components?
A: So far, no supply disruptions have been reported. West Pharma has activated its incident response protocols. The pharmaceutical industry relies on just-in-time delivery of components, so any prolonged IT outage could lead to delays. However, the company has not disclosed any material impact on production or quality. Customers are advised to monitor updates from West Pharma.
Q: Does OrganaBio’s new CDMO subsidiary compete with larger CDMOs like Lonza or Thermo Fisher?
A: OrganaBio’s subsidiary targets a specific niche: early-stage cell therapy developers that need custom sourcing of human cells as starting materials. By adding contract development and viral vector manufacturing, the company can offer a more integrated service. It is not a direct replacement for large-scale commercial manufacturers but rather a specialized partner for preclinical and Phase I production.
Q: Why are biotech companies selling their manufacturing facilities to CDMOs?
A: Building and maintaining a cGMP manufacturing facility costs hundreds of millions of dollars and requires specialized staff. For many biotechs, that capital is better spent on R&D and clinical trials. Selling the facility to a CDMO generates cash upfront, reduces fixed costs, and can still guarantee access to the site through a leaseback or supply agreement. This trend allows CDMOs to consolidate capacity and offer flexible contracts to multiple clients.